BSE Live
Dec 11, 16:01Prev. Close
2591.40
Open Price
2575.60
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
0.00 (0)
NSE Live
Dec 11, 15:59Prev. Close
2593.30
Open Price
2592.00
Bid Price (Qty.)
2622.10 (1)
Offer Price (Qty.)
0.00 (0)
| Profit & Loss account of GlaxoSmithKline Pharmaceuticals (in Rs. Cr.) | Mar 20 | Mar 19 | Mar 18 | Mar 17 | Mar 16 | |
| 12 mths | 12 mths | 12 mths | 12 mths | 12 mths | ||
| INCOME | ||||||
| Revenue From Operations [Gross] | 3,187.35 | 3,089.48 | 2,820.03 | 2,920.79 | 2,753.02 | |
| Less: Excise/Sevice Tax/Other Levies | 0.00 | 0.00 | 24.19 | 91.52 | 91.03 | |
| Revenue From Operations [Net] | 3,187.35 | 3,089.48 | 2,795.84 | 2,829.27 | 2,662.00 | |
| Total Operating Revenues | 3,224.68 | 3,128.53 | 2,871.69 | 2,902.99 | 2,735.19 | |
| Other Income | 77.56 | 101.48 | 53.52 | 72.01 | 121.83 | |
| Total Revenue | 3,302.24 | 3,230.01 | 2,925.21 | 2,975.00 | 2,857.01 | |
| EXPENSES | ||||||
| Cost Of Materials Consumed | 474.38 | 682.07 | 510.27 | 523.58 | 632.17 | |
| Purchase Of Stock-In Trade | 868.92 | 645.89 | 788.42 | 790.70 | 739.94 | |
| Operating And Direct Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Changes In Inventories Of FG,WIP And Stock-In Trade | -35.43 | 25.57 | -57.94 | 79.49 | -144.49 | |
| Employee Benefit Expenses | 628.55 | 537.20 | 523.40 | 483.01 | 443.37 | |
| Finance Costs | 6.34 | 0.55 | 0.19 | 0.25 | 0.00 | |
| Depreciation And Amortisation Expenses | 82.68 | 48.59 | 37.99 | 26.35 | 24.95 | |
| Other Expenses | 629.81 | 631.33 | 599.10 | 606.27 | 587.44 | |
| Total Expenses | 2,655.24 | 2,571.20 | 2,401.42 | 2,509.65 | 2,283.38 | |
| Profit/Loss Before Exceptional, ExtraOrdinary Items And Tax | 646.99 | 658.82 | 523.79 | 465.35 | 573.63 | |
| Exceptional Items | -324.49 | 4.89 | 17.80 | 45.73 | 2.31 | |
| Profit/Loss Before Tax | 322.50 | 663.71 | 541.58 | 511.08 | 575.94 | |
| Tax Expenses-Continued Operations | ||||||
| Current Tax | 235.31 | 192.82 | 204.34 | 162.97 | 207.49 | |
| Less: MAT Credit Entitlement | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Deferred Tax | -47.72 | 45.52 | -14.74 | 11.33 | -6.08 | |
| Tax For Earlier Years | 24.86 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Total Tax Expenses | 212.45 | 238.35 | 189.60 | 174.30 | 201.41 | |
| Profit/Loss After Tax And Before ExtraOrdinary Items | 110.05 | 425.36 | 351.99 | 336.78 | 374.53 | |
| Profit/Loss From Continuing Operations | 110.05 | 425.36 | 351.99 | 336.78 | 374.53 | |
| Profit/Loss For The Period | 110.05 | 425.36 | 351.99 | 336.78 | 374.53 | |
| OTHER ADDITIONAL INFORMATION | ||||||
| EARNINGS PER SHARE | ||||||
| Basic EPS (Rs.) | 6.50 | 25.11 | 41.56 | 39.76 | 44.22 | |
| Diluted EPS (Rs.) | 6.50 | 25.11 | 41.56 | 39.76 | 44.22 | |
| VALUE OF IMPORTED AND INDIGENIOUS RAW MATERIALS STORES, SPARES AND LOOSE TOOLS | ||||||
| Imported Raw Materials | 0.00 | 0.00 | 0.00 | 0.00 | 69.17 | |
| Indigenous Raw Materials | 0.00 | 0.00 | 0.00 | 0.00 | 567.80 | |
| STORES, SPARES AND LOOSE TOOLS | ||||||
| Imported Stores And Spares | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Indigenous Stores And Spares | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| DIVIDEND AND DIVIDEND PERCENTAGE | ||||||
| Equity Share Dividend | 338.81 | 296.46 | 254.11 | 423.52 | 529.39 | |
| Tax On Dividend | 69.64 | 60.94 | 51.73 | 86.22 | 107.77 | |
| Equity Dividend Rate (%) | 400.00 | 200.00 | 350.00 | 300.00 | 500.00 |
12.11.2025
GlaxoSmithKline Standalone September 2025 Net Sales at Rs 973.63 crore, down 2.64% Y-o-Y
07.11.2025
GlaxoSmithKline Consolidated September 2025 Net Sales at Rs 979.94 crore, down 3.05% Y-o-Y
12.08.2025
GlaxoSmithKline Consolidated June 2025 Net Sales at Rs 805.17 crore, down 1.16% Y-o-Y
01.08.2025
GlaxoSmithKline Standalone June 2025 Net Sales at Rs 804.83 crore, down 0.76% Y-o-Y